REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to tame aggressive blood cancers
Disease control TerminatedThis study tested whether combining two drugs, omacetaxine and venetoclax, could help control acute myeloid leukemia or myelodysplastic syndrome that had returned or stopped responding to other treatments in patients with a specific genetic change called RUNX1. The goal was to fi…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test new combo against tough blood cancers
Disease control TerminatedThis early-stage study tested a combination of two chemotherapy drugs, pevonedistat and belinostat, in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had returned or stopped responding to other treatments. The main goal was to find the highest dos…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control TerminatedThis study tested a combination of two chemotherapy drugs, venetoclax and azacitidine, for people with high-risk myelodysplastic syndromes (MDS) or related blood cancers. It aimed to find a safe dose and see if the treatment could control the disease, especially for patients whos…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC